Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Institute of Biomedical Engineering, Bogazici University, Istanbul 34684, Turkey.
Nanomedicine (Lond). 2019 Dec;14(24):3177-3191. doi: 10.2217/nnm-2019-0126. Epub 2019 Nov 14.
To investigate potential of magnetite iron oxide nanoparticles (MION) to sensitize cisplatin-resistant ovarian cancer cells to cisplatin, which to the best of found knowledge has not been reported previously. MION with a diameter of approximately 20 nm were synthesized, and characterized using Fourier transform infrared spectroscopy, powder x-ray diffraction and particle size analyzer. The synthesized MION have increased reactive oxygen species levels and decreased glutathione levels in cisplatin-resistant ovarian cancer cells (OVCAR-3 and SKOV-3). Using MTT, capsase-3 activity and live/dead assays, capability of the synthesized MION to sensitize cisplatin-resistant ovarian cancer cells has been illustrated. Thus, for further investigations, the synthesized MION can be considered as a potent agent enabling much more effective cisplatin-based therapies for ovarian cancer.
为了研究磁铁矿氧化铁纳米粒子（MION）是否有潜力使顺铂耐药的卵巢癌细胞对顺铂敏感，据我们所知，这在以前尚未有报道。我们合成了直径约为 20nm 的 MION，并通过傅里叶变换红外光谱、粉末 X 射线衍射和粒度分析仪进行了表征。合成的 MION 增加了顺铂耐药卵巢癌细胞（OVCAR-3 和 SKOV-3）中的活性氧水平，降低了谷胱甘肽水平。通过 MTT、半胱天冬酶-3 活性和死活检测，说明了合成的 MION 使顺铂耐药卵巢癌细胞敏感的能力。因此，对于进一步的研究，可以考虑将合成的 MION 作为一种有效的药物，为卵巢癌提供更有效的顺铂治疗。
